+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 12Years - 89Years
All Genders
ID07645820

Study of the Nevisense Go Device for Early Detection of Flares in Adolescents and Adults with Atopic Dermatitis

Led by Castle Biosciences Incorporated · Updated on 2026-10-20

450

Participants Needed

13

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the investigational Nevisense Go device for collecting skin measurements from people with atopic dermatitis AD, a condition marked by flare-ups of worsening skin symptoms. The study focuses on participants aged 12 to 89 years who have experienced recent AD flares. It is based on the idea that changes in skin barrier function may happen before visible signs or symptoms of a flare appear. Participants will use the Nevisense Go device at home for about 90 days to measure electrical properties of their skin related to skin barrier function. The study is observational, meaning device measurements will not guide treatment or care. Alongside device use, participants will complete electronic symptom diaries and attend up to five in-person study visits during the study period. During the study, researchers will assess the relationship between skin measurements and AD flares, develop and validate an algorithm using the device data, and evaluate AD severity through patient-reported and clinician-reported outcomes. They will also assess flare resolution, device feasibility, and participant adherence. The total participation lasts approximately 90 days with repeated measurements and study visits throughout this time.

CONDITIONS

Brief Title

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Research Team

C

Clare Johnson E VP Clinical Research

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here